New pill targets Hard-to-Treat cancers in early trial
NCT ID NCT06305247
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for signs that it can shrink tumours. All participants take the drug by mouth in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPN01194 (an ERK1/2 inhibitor taken orally)
What this could lead to
If successful, this could point toward a new treatment option for certain advanced solid tumours that have not responded to other therapies.
What could go wrong
This is an early, small trial (36 participants) focused on safety and dosing. The drug may not shrink tumours or could cause side effects. It is too soon to know if it will work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barcelona - Val D'Hebron
Barcelona, Spain
-
Centre Léon Bérard - Lyon
Lyon, France
-
Fundacion Jimenez Diaz - Madrid
Madrid, Spain
-
IGR-Villejuif
Villejuif, France
-
Institut de Cancerologie de l'Ouest (St-Herblain)
Saint-Herblain, France
-
M.D. Anderson Cancer Center Madrid
Madrid, Spain
-
Paris Saint-Louis
Paris, France
-
Sarah Cannon Research Institute (SCRI) - Nashville
Nashville, Tennessee, 37203, United States
-
The Angeles Clinic and Research Institute - California
Los Angeles, California, 90025, United States
-
Virginia Cancer Specialist
Fairfax, Virginia, 22031, United States
-
Yale Cancer Center - New Heaven
New Haven, Connecticut, 06510, United States